Research Project

Project Title:

Rescue Therapy With the Human Anti-CD38 Antibody MOR202 (Felzartamab) in Patients With Membranous Nephropathy Who Failed Anti-CD20 Target Therapy (MONET)

Project Type:

Clinical Trial, Enrolment ongoing

Disease group(s):

Immune glomerulopathies

Project Summary:

CD38-targeted therapy with MOR202 may abrogate autoantibody-dependent mechanisms in patients with plasma-cell mediated forms of MN who failed previous treatment with rituximab and second-generation anti-CD20 monoclonal antibodies such as ofatumumab. With this background, MOR202 therapy may have an indication for patients with MN and NS resistant to CD20 targeted therapy.

Lead principal investigator(s):

Piero Ruggenenti, Bergamo


Laura Cappelletti, Bergamo
Amantia Imeraj, Bergamo
Alessia Gennarini, Bergamo

Project Period:

10/2021   -   10/2024

« Back to research page